Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change
BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis
2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees.
To have the chance to heal so many people, save lives and restart economies is a responsibility not to be taken lightly. ...